Legal & regulatory status
No major drug regulator has approved Melanotan II for any use, and several have actively moved to ban its sale and remo…
Banned everywhere, sold everywhere: the regulatory reality
No major drug regulator has approved Melanotan II for any use, and several have actively moved to ban its sale and remove its advertising. Yet it remains widely available online behind a "research chemical" label. This unit maps that contradiction: the worldwide regulatory status, the legal fiction that sustains the market, and the unregulated-supply risks that follow.
Understanding the regulatory picture is not legal trivia; it is the clearest evidence of how seriously health authorities view a drug that marketing presents as harmless.
Key terms
The worldwide status
Across every major jurisdiction, the verdict on MT-II is the same: not approved, and in many places actively targeted for removal. The agencies differ in wording and enforcement, but none of them treats MT-II as a legitimate product. Tap each jurisdiction to see its specific stance.
The uniformity is the message. When the FDA, TGA, MHRA, EMA, HPRA, and the anti-doping system all independently refuse to sanction a substance, that consensus is itself a strong signal. Note the recurring confusion the EMA entry flags: the approval of afamelanotide (Melanotan I) does not extend to MT-II, a distinction vendors deliberately blur.
AdvancedWhy MT-I being approved does not help MT-II
Afamelanotide (Melanotan I) earned approval as SCENESSE for a rare light-sensitivity disease through proper trials of a specific, MC1R-selective molecule delivered as a controlled implant. MT-II is a different compound, non-selective, unstudied at scale, and sold without quality control. Regulators approve molecules and indications, not names, so the SCENESSE approval gives MT-II no legal or scientific cover whatsoever.